Rodent Cell, Per Se Patents (Class 435/352)
Rat (i.e., rattus) (Class 435/353)
Mouse (i.e., mus) (Class 435/354)
Chinese hamster ovary (i.e., cho) (Class 435/358)
  • PEPTIDES
    Publication number: 20130259884
    Abstract: The application discloses peptides capable of preventing or treating fungal disease, including fungal allergy disease.
    Type: Application
    Filed: September 23, 2011
    Publication date: October 3, 2013
    Applicant: ALERGENETICA SL
    Inventors: Nigel Stuart Dunn-Coleman, Maria R. Diaz-Torres, Brian Miller
  • ANCESTRAL PROTEINS
    Publication number: 20130252307
    Abstract: The invention provides a method for increasing the stability and/or activity of a polypeptide at low pH and/or elevated temperatures. The invention further provides a method for increasing the melting temperature of a polypeptide. Also provided are paleoenzymologically reconstructed thioredoxin polypeptides having activity at higher temperatures and/or lower pH than extant thioredoxin polypepetides, as well as paleoenzymologically reconstructed thioredoxin polypeptides having higher melting temperatures than extant thioredoxin polypepetides.
    Type: Application
    Filed: July 15, 2011
    Publication date: September 26, 2013
    Applicant: GEORGIA TECH RESEARCH CORPORATION
    Inventors: Julio M. Fernandez, Raul Perez-Jimenez, Eric Gaucher, Pallav Kosuri
  • OPTICAL CONTROL OF PROTEIN ACTIVITY AND LOCALIZATION BY FUSION TO PHOTOCHROMIC PROTEIN DOMAINS
    Publication number: 20130252282
    Abstract: Engineered fusion proteins comprising photochromic protein domains are disclosed. In particular, the inventors have constructed fusion proteins containing photoswitchable photochromic fluorescent protein domains linked to selected proteins and shown that such fusion proteins can be used to control the activity or localization of selected proteins with light.
    Type: Application
    Filed: March 21, 2013
    Publication date: September 26, 2013
    Applicant: The Board of Trustees of the Leland Stanford Junior University
    Inventor: The Board of Trustees of the Leland Stanford Junior University
  • Humanized Anti-CXCR5 Antibodies, Derivatives Thereof And Their Use
    Publication number: 20130243783
    Abstract: The present invention relates to humanized antibodies that specifically bind to CXCR5 and can, for example, inhibit CXCR5 function. The invention also includes uses of the antibodies to treat or prevent CXCR5 related diseases or disorders.
    Type: Application
    Filed: March 11, 2013
    Publication date: September 19, 2013
    Applicant: SANOFI
    Inventors: Renata Lee, Vincent Mikol, Elizabeth Allen, Norman Ruetsch, Beatrice Cameron, Thomas Oligino, Nicholas Baurin
  • GENETIC PRODUCTS DIFFERENTIALLY EXPRESSED IN TUMORS AND USE THEREOF
    Publication number: 20130243796
    Abstract: The invention relates to the identification of genetic products that are expressed in association with a tumor and the nucleic acid coding therefor. The invention relates to the therapy and diagnosis of diseases in which the genetic products that are expressed in association with a tumor are expressed in an aberrant manner. The invention also relates to proteins, polypeptides, and peptides which are expressed in association with a tumor and the nucleic acids coding therefor.
    Type: Application
    Filed: March 12, 2013
    Publication date: September 19, 2013
    Inventors: Ugur Sahin, Özlem Türeci, Michael Koslowski
  • INTERGENIC REGIONS AS INSERTION SITES IN THE GENOME OF MODIFIED VACCINIA VIRUS ANKARA (MVA)
    Publication number: 20130243813
    Abstract: The present invention relates to novel insertion sites useful for the integration of exogenous sequences into the Modified Vaccinia Ankara (MVA) virus genome. The present invention further provides plasmid vectors to insert exogenous DNA into the genome of MVA. Furthermore, the present invention provides recombinant MVA comprising an exogenous DNA sequence inserted into the new insertion site as medicine or vaccine.
    Type: Application
    Filed: May 2, 2013
    Publication date: September 19, 2013
    Applicant: BAVARIAN NORDIC A/S
    Inventors: PAUL HOWLEY, SONJA LEYRER
  • EXPRESSION VECTOR FOR HIGH LEVEL EXPRESSION OF RECOMBINANT PROTEINS
    Publication number: 20130244280
    Abstract: The present invention provides an expression vector for the production of proteins and peptides comprising a promoter operably linked to gene of interest, TPL and VA genes I and II, matrix attachment regions (MARs)/SARs, and antibiotic marker. The vector is transfected in suitable host cell.
    Type: Application
    Filed: October 10, 2011
    Publication date: September 19, 2013
    Applicant: CADILA HEALTHCARE LIMITED
    Inventors: Aashini Parikh, Arun Singh, Sanjeev Kumar Mendiratta, Ajit K Gupta, Mansi Jakhade
  • ALPHA 1-3 N-GALACTOSYLSTRANSFERASE WITH ALTERED DONOR SPECIFICITIES, COMPOSITIONS AND METHODS OF USE
    Publication number: 20130243690
    Abstract: The invention generally features compositions and methods based on the structure-based design of alpha 1-3 N-Acetylgalactosaminyltransferase (alpha 3 GalNAc-T) enzymes from alpha 1-3galactosyltransferase (a3Gal-T) that can transfer 2?-modified galactose from the corresponding UDP-derivatives due to substitutions that broaden the alpha 3Gal-T donor specificity and make the enzyme a3 GalNAc-T.
    Type: Application
    Filed: April 11, 2013
    Publication date: September 19, 2013
    Applicant: Government of the United Sates of America, as represented by the Secretary Department of Health
    Inventors: Pradman K. Qasba, Boopathy Ramakrishnan, Elizabeth Boeggeman, Marta Pasek
  • Fusion Protein Having Factor VII Activity
    Publication number: 20130236945
    Abstract: A fusion protein comprising factor VII (FVII) and transferrin according to the present invention has an improved specific activity of FVII compared to existing FVII fusion proteins comprising other fusion partners than transferrin, and thus can be effectively used in a therapy using FVII.
    Type: Application
    Filed: June 7, 2011
    Publication date: September 12, 2013
    Applicant: SK CHEMICALS CO., LTD
    Inventors: In-Young Song, Hun-Taek Kim, Bong-Yong Lee, Mahn-Hoon Park, Ho-Soon Lee, Yun Jung Lim, Ji-Hye Lee, Seo Yeon Son, Min-Sun Kim
  • SEQUENCE DIVERSITY GENERATION IN IMMUNOGLOBULINS AND OTHER PROTEINS
    Publication number: 20130236931
    Abstract: An in vitro system for generating sequence, and thus structural, diversity in proteins is described. The system can be constructed using appropriately selected nucleic acid molecules that encode regions of a selected protein or proteins and recombination signal sequences (RSS). The selected protein(s) can be, for example, immunoglobulin (Ig) V, D, J and/or C regions, regions of a non-immunoglobulin (non-Ig) protein, or a combination of Ig regions and non-Ig regions. Assembly of such appropriately selected components and their introduction into suitable recombination-competent host cells allows for recombination between the RSS sequences and introduction of sequence and structural diversity into the protein(s).
    Type: Application
    Filed: February 12, 2013
    Publication date: September 12, 2013
    Inventors: Michael Gallo, Jaspal Singh Kang, Craig Robin Pigott
  • Viral expression plasmids for production of proteins, antibodies, enzymes, virus-like particles and for use in cell-based assays
    Publication number: 20130236958
    Abstract: This disclosure shows that the EBV FR-element comprised of EBNA1 multimeric binding sites can provide the stable maintenance replication function to the mouse polyomavirus (PyV) core origin plasmids in the presence of BPV-1 E2 protein and PyV large T-antigen (LT).
    Type: Application
    Filed: January 23, 2013
    Publication date: September 12, 2013
    Applicant: ICOSAGEN CELL FACTORY OU
    Inventors: Toomas SILLA, Ingrid TAGEN, Jelizaveta GEIMANEN, Kadri JANIKSON, Aare ABROI, Ene USTAV, Mart USTAV, Tiiu MANDEL, Urve TOOTS, Andres TOVER, Anne KALLING, Radi TEGOVA
  • EXPRESSION VECTOR AND METHODS OF PRODUCING HIGH LEVELS OF PROTEINS
    Publication number: 20130236957
    Abstract: A process for high expression of protein of interest using an expression vector. The process comprises at least the following regulatory elements: a) a CMV promoter, or a functional variant thereof, b) an intron, c) TPL or a functional variant thereof, d) VA gene or a functional variant thereof, and e) a bovine growth hormone polyadenylation sequence or a functional variant thereof.
    Type: Application
    Filed: May 15, 2012
    Publication date: September 12, 2013
    Inventors: Arun K. SINGH, Ashish Goel, Sanjeev K. Mendiratta
  • NUCLEIC ACID FRAGMENTS FROM A RIBOSOMAL PROTEIN PROMOTER FOR ENHANCING GENE EXPRESSION
    Publication number: 20130236956
    Abstract: The present invention relates to nucleic acid fragments and constructs comprising genomic nucleotide sequences from the promoter region of a 60S ribosomal protein L32 gene (RPL32), for the production of a gene product of interest in a eukaryotic, preferably mammalian, host cell in the presence of a stringent selectable marker. The invention further relates to host cells comprising the nucleic acid constructs, to methods for generating the host cells and to methods for producing a gene product of interest using the host cells.
    Type: Application
    Filed: August 31, 2011
    Publication date: September 12, 2013
    Inventors: Arie Pieter Otte, Femke Hoeksema, John Antonious Verhees, Henricus Johannes Maria Van Blokland
  • Chimeric Retinoid X Receptors and Their Use in a Novel Ecdysone Receptor-Based Inducible Gene Expression System
    Publication number: 20130232588
    Abstract: This invention relates to the field of biotechnology or genetic engineering. Specifically, this invention relates to the field of gene expression. More specifically, this invention relates to a novel ecdysone receptor/chimeric retinoid X receptor-based inducible gene expression system and methods of modulating gene expression in a host cell for applications such as gene therapy, large-scale production of proteins and antibodies, cell-based high throughput screening assays, functional genomics and regulation of traits in transgenic organisms.
    Type: Application
    Filed: September 14, 2012
    Publication date: September 5, 2013
    Applicant: Intrexon Corporation
    Inventors: Marianna Zinovievna KAPITSKAYA, Subba Reddy Palli
  • PROTEIN KINASE CK2 GENE MUTATIONS, AMPLIFICATIONS AND POLYMORPHISMS IN HUMAN CANCERS AND METHODS OF USE
    Publication number: 20130230852
    Abstract: The present disclosure provides methods and compositions for diagnosis and for providing a prognosis of a cancer patient by assessing CK2 alpha 1 pseudogene (CSNK2A1P) status. The present disclosure also provides polypeptide, polynucleotide, host cell, and transgenic animal compositions associated with CSNK2A1P.
    Type: Application
    Filed: July 1, 2011
    Publication date: September 5, 2013
    Applicant: The Regents of the University of California
    Inventors: Liang You, Zhidong Xu, Biao He, David Jablons
  • PROCESS FOR MAKING RECOMBINANT ANTIDOTE TO FACTOR XA INHIBITOR
    Publication number: 20130230901
    Abstract: Disclosed are methods and isolated cells useful for the improved production of function fXa derivative protein that acts as a fXa inhibitor antidote. One aspect relates to an isolated cell comprising the r-Antidote polynucleotide and Furin polynucleotide. Another aspect relates to a method for preparing the cleaved two-chain r-Antidote by expressing, in a cell, the pre-processed r-Antidote polypeptide and a Furin polypeptide.
    Type: Application
    Filed: February 13, 2013
    Publication date: September 5, 2013
    Applicant: Portola Pharmaceuticals, Inc.
    Inventors: Genmin LU, Pamela B. Conley, Uma Sinha
  • NOVEL COLLECTIN
    Publication number: 20130230918
    Abstract: Novel collectin related molecules i.e., a novel collectin gene comprising a nucleotide sequence set out in SEQ ID NO: 1, and a novel collectin comprising an amino acid sequence set out in SEQ ID NO: 2, which are expected to exhibit anti-bacterial, anti-viral activity or the like especially in human body, and methods in which these molecules are used are provided.
    Type: Application
    Filed: February 10, 2012
    Publication date: September 5, 2013
    Applicant: FUSO PHARMACEUTICAL INDUSTRIES, LTD.
    Inventor: Nobutaka Wakamiya
  • IDENTIFICATION OF ANTIBODIES SPECIFIC FOR LYSSAVIRUSES AND METHODS OF THEIR USE
    Publication number: 20130224207
    Abstract: Described herein is a method of identifying a monoclonal antibody (or antigen-binding fragment thereof) that specifically binds a plurality of lyssaviruses for use in post-exposure rabies prophylaxis or in the treatment of clinical rabies. The method includes using a naïve antibody phage display library to screen for phage clones that bind whole recombinant rabies virus or cells expressing glycoprotein from multiple lyssaviruses (such as RABV, MOKV and WCBV) and/or specifically bind recombinant glycoprotein from different lyssaviruses.
    Type: Application
    Filed: October 18, 2011
    Publication date: August 29, 2013
    Applicants: Department of Health and Human Services, Centers for Disease Control and Prevention
    Inventors: Todd G. Smith, Xianfu Wu
  • Methods for Generating Cardiomyocytes
    Publication number: 20130216503
    Abstract: The present disclosure provides method of generating cardiomyocytes from post-natal fibroblasts. The present disclosure further provides cells and compositions for use in generating cardiomyocytes.
    Type: Application
    Filed: April 26, 2011
    Publication date: August 22, 2013
    Applicant: THE J. DAVID GLADSTONE INSTITUTES
    Inventors: Deepak Srivastava, Masaki Ieda
  • Chimeric Clotting Factors
    Publication number: 20130216513
    Abstract: Chimeric clotting factors which localize the therapeutic to sites of coagulation (e.g., by being targeted to platelets or being activatable at sites of coagulation), have reduced clearance rates, have improved manufacturability, have reduced thrombogenicity, have enhanced activity, or have more than one of these characteristics are described as are methods for making chimeric clotting factors and methods for improving hemostasia using these clotting factors.
    Type: Application
    Filed: July 11, 2011
    Publication date: August 22, 2013
    Applicant: Biogen Idec Hemophilia Inc.
    Inventors: Joe Salas, Robert Peters, Alan Bitonti
  • FIBRONECTIN BASED SCAFFOLD DOMAIN PROTEINS THAT BIND PCSK9
    Publication number: 20130210703
    Abstract: The present invention relates to fibronectin based scaffold domain proteins that bind PCSK9. The invention also relates to the use of the innovative proteins in therapeutic applications to treat atherosclerosis, hypercholesterolemia and other cholesterol related diseases. The invention further relates to cells comprising such proteins, polynucleotides encoding such proteins or fragments thereof, and to vectors comprising the polynucleotides encoding the innovative protein.
    Type: Application
    Filed: March 15, 2013
    Publication date: August 15, 2013
    Applicant: Bristol-Myers Squibb Company
    Inventor: Bristol-Myers Squibb Company
  • Methods and Therapeutics Comprising Ligand-Targeted ELPs
    Publication number: 20130210747
    Abstract: Disclosed herein are novel methods and compositions for targeting drug delivery systems to specific cells. One aspect relates to a drug delivery system comprising an elastin-like peptide (ELP) component and a ligand selected from the group consisting of mIgA and knob capable of either drug encapsulation or drug attachment. Further aspects relate to drug delivery systems comprising an elastin-like peptide (ELP) component and a ligand; wherein the ligand specifically binds to a receptor selected from the group consisting of CAR and pIgR. Further aspects include the novel transcytosing properties of the elastin-like peptide and the ligand, knob. Also provided are methods and pharmaceutical compositions comprising the disclosed therapeutics.
    Type: Application
    Filed: February 11, 2013
    Publication date: August 15, 2013
    Applicant: UNIVERSITY OF SOUTHERN CALIFORNIA
    Inventor: University of Southem California
  • VACCINES FOR USE IN THE PROPHYLAXIS AND TREATMENT OF INFLUENZA VIRUS DISEASE
    Publication number: 20130209499
    Abstract: Provided herein are polypeptides comprising portions of the influenza virus hemagglutinin, compositions comprising such polypeptides that can be used as immunogens in vaccines and methods of their use to generate an immune response against multiple influenza subtypes in a subject.
    Type: Application
    Filed: February 18, 2011
    Publication date: August 15, 2013
    Applicant: Mount Sinai School of Medicine
    Inventors: Adolfo Garcia-Sastre, Peter Palese, Gens S. Tan, Taia T. Wang
  • Engineered plant cysteine proteases and their uses
    Publication number: 20130196413
    Abstract: The present invention relates to potato virus NIa protease variants or fragments thereof, polynucleotides encoding them, and methods of making and using the foregoing.
    Type: Application
    Filed: March 22, 2013
    Publication date: August 1, 2013
    Applicant: CENTOCOR ORTHO BIOTECH INC.
    Inventors: Ellen Chi, Michael Hunter, Ronald Swanson
  • PROTEIN PRODUCTION
    Publication number: 20130196430
    Abstract: The invention concerns the field of protein production and cell culture technology. CERT is identified as a novel in vivo PKD substrate. Phosphorylation on serine 132 by PKD decreases the affinity of CERT towards its lipid target phosphatidylinositol 4-phosphate at Golgi membranes and reduces ceramide transfer activity, identifying PKD as a regulator of lipid homeostasis. The present invention shows that CERT in turn is critical for PKD activation and PKD dependent protein cargo transport to the plasma membrane. The interdependence of PKD and CERT is thus a key to the maintenance of Golgi membrane integrity and secretory transport.
    Type: Application
    Filed: June 12, 2012
    Publication date: August 1, 2013
    Applicant: BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG
    Inventors: Hitto KAUFMANN, Lore FLORIN, Eric BECKER, Monilola OLAYIOYE, Angelika HAUSSER, Tim FUGMANN
  • Leafhopper ecdysone receptor nucleic acids, polypeptides, and uses thereof
    Patent number: 8497093
    Abstract: The present invention relates to a novel isolated leafhopper ecdysone receptor polypeptide. The invention also relates to an isolated nucleic acid encoding the leafhopper ecdysone receptor polypeptide, to vectors comprising them and to their uses, in particular in methods for modulating gene expression in an ecdysone receptor-based gene expression modulation system and methods for identifying molecules that modulate leafhopper ecdysone receptor activity.
    Type: Grant
    Filed: August 16, 2011
    Date of Patent: July 30, 2013
    Assignee: Intrexon Corporation
    Inventor: Subba Reddy Palli
  • Use of Molecular Chaperones for the Enhanced Production of Secreted, Recombinant Proteins in Mammalian Cells
    Publication number: 20130189776
    Abstract: The present invention relates to a method for increased production of a secreted, recombinant protein product through the introduction of molecular chaperones in a mammalian host cell. The present invention also relates to a mammalian host cell with enhanced expression of a secreted recombinant protein product by coexpressing at least one chaperone protein.
    Type: Application
    Filed: March 6, 2013
    Publication date: July 25, 2013
    Applicant: BAYER PHARMACEUTICALS CORPORATION
    Inventor: BAYER PHARMACEUTICALS CORPORATION
  • GROWTH FACTOR ISOFORM
    Publication number: 20130184333
    Abstract: An isolated VEGF polypeptide having anti-angiogenic activity, said polypeptide including the amino acid sequence of SEQ. ID NO. 1, or variants thereof.
    Type: Application
    Filed: February 1, 2013
    Publication date: July 18, 2013
    Applicant: UNIVERSITY OF BRISTOL
    Inventor: University Of Bristol
  • FIBRONECTIN BASED SCAFFOLD PROTEINS HAVING IMPROVED STABILITY
    Publication number: 20130184212
    Abstract: The present application provides fibronectin based scaffold proteins associated with improved stability. The application also relates to stable formulations of fibronectin based scaffold proteins and the use thereof in diagnostic, research and therapeutic applications. The application further relates to cells comprising such proteins, polynucleotides encoding such proteins or fragments thereof, and to vectors comprising such polynucleotides.
    Type: Application
    Filed: May 26, 2011
    Publication date: July 18, 2013
    Applicant: BRISTOL-MYERS SQUIBB COMPANY
    Inventors: Ray Camphausen, John O'Loughlin, Bernice Yeung, Yihong Zhang
  • Modified factor IX polypeptides and uses thereof
    Publication number: 20130177541
    Abstract: Modified Factor IX (FIX) polypeptides and uses thereof are provided. Such modified FIX polypeptides include FIXa and other forms of FIX. Among the modified FIX polypeptides provided are those that have altered activities, typically altered procoagulant activity, including increased procoagulant activities. Hence, such modified polypeptides are therapeutics.
    Type: Application
    Filed: November 3, 2011
    Publication date: July 11, 2013
    Inventors: Edwin L. Madison, Christopher Thanos, Grant Ellsworth Blouse
  • TRANSGENIC MOUSE MODEL EXPRESSING AMYLOID BETA 4-42 PEPTIDE
    Publication number: 20130179998
    Abstract: The present invention describes a novel transgenic mouse model for the common sporadic form of Alzheimer's disease. More particularly, the invention relates to a nucleotide sequence encoding A? 4-42 in functional linkage with at least a promoter, signal peptide sequence and a polyadenylation signal sequence, a cell and a transgenic non-human animal comprising said nucleotide sequence, and their respective use in screening methods.
    Type: Application
    Filed: June 8, 2010
    Publication date: July 11, 2013
    Inventors: Thomas Bayer, Oliver Wirths
  • NOVEL REGULATORY ELEMENTS
    Publication number: 20130177943
    Abstract: The invention concerns novel regulatory elements as well as related vectors and cells. Furthermore, it relates to methods of improving expression of polypeptides from nucleic acids such as cloned genes and to the production of various polypeptides in host cells using said novel regulatory elements. Additionally, the invention relates to uses of said novel regulatory elements as insulators, in gene therapy or for improving host cell lines.
    Type: Application
    Filed: February 22, 2013
    Publication date: July 11, 2013
    Applicant: BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG
    Inventor: Barbara ENENKEL
  • BIOCATALYSTS AND METHODS FOR THE SYNTHESIS OF (1R,2R)-2-(3,4-DIMETHOXYPHENETHOXY)CYCLOHEXAMINE
    Publication number: 20130164794
    Abstract: The disclosure provides transaminase polypeptides capable of converting the substrate, 2-(3,4-dimethoxyphenethoxy)cyclohexanone to the trans diastereomer product (1R,2R)-2-(3,4-dimethoxyphenethoxy)cyclohexanamine in at least a 2:1 diastereomeric ratio relative to the cis diastereomer (1R,2S)-2-(3,4-dimethoxyphenethoxy)cyclohexanamine. The disclosure also provides polynucleotides, vectors, host cells, and methods of making and using the transaminase polypeptides in processes for preparing (1R,2R)-2-(3,4-dimethoxyphenethoxy)cyclohexanamine and its analogs, which can product compounds can be further used to prepare the aminocyclohexylether compound, (3R)-1-[(1R,2R)-2-[2-(3,4-dimethoxyphenyl)ethoxy]cyclohexyl]pyrrolidin-3-ol, which is an ion channel blocker.
    Type: Application
    Filed: August 8, 2011
    Publication date: June 27, 2013
    Applicant: CODEXIS, INC.
    Inventors: John Limanto, Gregory Beutner, Brendan Grau, Jacob Janey, Artis Klapars, Eric Ashley, Hallena R. Strotman, Matthew D. Truppo, Gregory Hughes, Fabien L. Cabirol, Anupam Gohel, Steven J. Collier, Jack Liang, Marissa Mock, Emily Mundorff, Scott Novick, Derek Smith
  • POLYNUCLEOTIDES AND CONSTRUCTS ENCODING SFLT1-14 AND METHOD FOR EFFICIENT PROPAGATION AND EXPRESSION THEREOF
    Publication number: 20130164270
    Abstract: The present invention relates to engineered polynucleotides and constructs comprising nucleic acid sequences encoding a specific splice-variant (sFLT1-14) of the VEGFR family Flt-1, methods for efficient propagation and expression thereof and compositions and uses thereof. More particularly, the invention relates to isolated polynucleotides comprising a nucleic acid sequence coding for sFlt1-14 or any fragment thereof comprising the serine-rich C-terminus region of said sFlt1-14, wherein at least one of the TCA serine coding codons in said serine-rich C-terminus region of sFlt1-14 as encoded by the nucleic acid sequence of SEQ ID NO. 1, is replaced by any one of TCT, TCC, TCG, AGT, AGC. The invention further provides compositions and method of treating VEGF-associated medical conditions using the polynucleotides of the invention.
    Type: Application
    Filed: July 29, 2010
    Publication date: June 27, 2013
    Applicant: Yissum Research Developement Company of the Hebrew University of Jerusalem Ltd.
    Inventors: Eli Keshet, Shay Sela
  • MUTANT G-CSF FUSION PROTEIN, AND PREPARATION AND USE THEREOF
    Publication number: 20130164251
    Abstract: The present invention relates to a mutant G-CSF fusion protein. The mutant G-CSF fusion protein is a fusion protein having the activity of stimulating the proliferation of neutrophilic granulocytes, and having a basic structure of G-CSF/carrier protein or carrier protein/G-CSF; wherein the G-CSF moiety comprises multipoint substitutions thus resulting in changes in biological activity and binding affinity. Compared with existing products, the mutant G-CSF fusion protein in the present invention has longer half-life and higher biological activity. Administration of the pharmaceutical preparation containing this mutant G-CSF fusion protein could be used in the treating neutropenia.
    Type: Application
    Filed: June 30, 2010
    Publication date: June 27, 2013
    Inventors: Xiaofang Wen, Yiliang Wu, Yefei Wang, Zhiyu Yang, Min Fan, Yujiao Wang, Xiaochun Fang, You Lu
  • METHODS AND COMPOSITIONS FOR INACTIVATING GLUTAMINE SYNTHETASE GENE EXPRESSION
    Publication number: 20130164785
    Abstract: Disclosed herein are methods and compositions for inactivating a glutamine synthetase (GS) gene, using fusion proteins comprising a zinc finger protein and a cleavage domain or cleavage half-domain. Polynucleotides encoding said fusion proteins are also provided, as are cells comprising said polynucleotides and fusion proteins.
    Type: Application
    Filed: September 6, 2012
    Publication date: June 27, 2013
    Inventors: Pei-Qi Liu, Jeffrey C. Miller
  • COLORIMETRIC AND FLUORESCENT PROTEINS
    Publication number: 20130157284
    Abstract: The invention relates to intracellular lipid binding proteins that bind retinoids and/or dye ligands and that are modified to transmit or emit light at a variety of different wavelengths.
    Type: Application
    Filed: March 23, 2011
    Publication date: June 20, 2013
    Applicant: Board of Trustees of Michigan State University
    Inventors: Babak Borhan, James Geiger, Wenjing Wang, Chrysoula Vasileiou, Kin Sing Lee, Tetyana Berbasova
  • TRANSGENIC ANIMAL AS A MODEL FOR IDENTIFYING ADULT STEM CELLS, AND USES THEREOF
    Publication number: 20130160151
    Abstract: The present invention relates to the use of a transgenic non-human animal, such as a mouse, expressing a reporter gene detectable by a chromogenic, luminescent or fluorescent signal which identifies the cells that express Pw1, or of Pw1-expressing cells or tissues isolated therefrom, as a model for screening a candidate substance for its ability to stimulate adult stem cells, or for monitoring cell aging.
    Type: Application
    Filed: July 6, 2011
    Publication date: June 20, 2013
    Applicant: Universite Pierre et Marie Curie (PARIS 6)
    Inventors: David Sassoon, Vanessa Besson, Giovanna Marazzi
  • NOVEL INTERGENIC ELEMENTS FOR ENHANCING GENE EXPRESSION
    Publication number: 20130157312
    Abstract: The present invention relates to nucleic acid fragments and constructs comprising genomic nucleotide sequences, which are present upstream of Rb1 and p15C that are associated with intergenic transcription, for the production of a gene product of interest in a eukaryotic, preferably mammalian, host cell in the presence of a stringent selectable marker. The invention further relates to host cells comprising the nucleic acid constructs, to methods for generating the host cells and to methods for producing a gene product of interest using the host cells.
    Type: Application
    Filed: June 15, 2011
    Publication date: June 20, 2013
    Inventors: Arie Pieter Otte, Michel Siep, John Antonius Verhess, Femke Hoeksema
  • COMPOSITIONS AND METHODS FOR MODULATING HEMOSTASIS
    Publication number: 20130156848
    Abstract: Novel thrombin/prothrombin protease/zymogen variants which have anticoagulation activity and methods of use thereof are disclosed.
    Type: Application
    Filed: December 10, 2012
    Publication date: June 20, 2013
    Inventors: Sriram Krishnaswamy, Elsa P. Bianchini, Steven Orcutt
  • HUMAN T2R NUCLEIC ACID SEQUENCES
    Publication number: 20130150263
    Abstract: Newly identified mammalian taste-cell-specific G Protein-Coupled Receptors and the genes encoding said receptors are described. Specifically, T2R taste G Protein-Coupled Receptors that are believed to be involved in bitter taste sensation, and the genes encoding the same, are described, along with methods for isolating such genes and for isolating and expressing such receptors. Methods for representing taste perception of a particular tastant in a mammal are also described, as are methods for generating a novel molecules or combinations of molecules that elicit a predetermined taste perception in a mammal, and methods for simulating one or more tastes.
    Type: Application
    Filed: May 27, 2011
    Publication date: June 13, 2013
    Inventor: Jon Elliot Adler
  • HIGH EFFICIENCY GENE TRANSFER AND EXPRESSION IN MAMMALIAN CELLS BY AMULTIPLE TRANSFECTION PROCEDURE OF MAR SEQUENCES
    Publication number: 20130143264
    Abstract: The present invention relates to purified and isolated DNA sequences having protein production increasing activity and more specifically to the use of matrix attachment regions (MARs) for increasing protein production activity in a eukaryotic cell. Also disclosed is a method for the identification of said active regions, in particular MAR nucleotide sequences, and the use of these characterized active MAR sequences in a new multiple transfection method.
    Type: Application
    Filed: June 28, 2012
    Publication date: June 6, 2013
    Applicant: SELEXIS SA
    Inventors: Mermod Nicolas, Pierre Alain Girod, Philipp Bucher, Duc-Quang Nguyen, David Calabrese, Damien Saugy, Stefania Puttini
  • ZCYTOR17 HETERODIMERIC CYTOKINE RECEPTOR POLYNUCLEOTIDES
    Publication number: 20130143265
    Abstract: Novel polypeptide combinations, polynucleotides encoding the polypeptides, and related compositions and methods are disclosed for zcytor17-containing multimeric or heterodimer cytokine receptors that may be used as novel cytokine antagonists, and within methods for detecting ligands that stimulate the proliferation and/or development of hematopoietic, lymphoid and myeloid cells in vitro and in vivo. The present invention also includes methods for producing the multimeric or heterodimeric cytokine receptor, uses therefor and antibodies thereto.
    Type: Application
    Filed: January 14, 2013
    Publication date: June 6, 2013
    Applicant: ZymoGenetics, Inc.
    Inventor: ZymoGenetics, Inc.
  • NOVEL MODIFIED LIVE-ATTENUATED VACCINES (MLV) CREATED BY DNA SHUFFLING AGAINST PORCINE REPRODUCTIVE AND RESPIRATORY SYNDROME VIRUS (PRRSV)
    Publication number: 20130142824
    Abstract: The present invention provides a novel infectious cDNA clone of porcine reproductive and respiratory syndrome virus (PRRSV), particularly for PRRSV strain VR2385; an improved DNA-launched reverse genetics system for PRRSV; infectious chimeric PRRSV viruses generated through DNA shuffling; modified live- attenuated virus vaccines (MLV) using DNA shuffled chimeric viruses; chimeric viral proteins produced through shuffled chimeric viruses; PRRSV antigens and subunit vaccines based on shuffled chimeric viral proteins; and method of producing broadly protective PRRSV vaccines using DNA shuffling techniques.
    Type: Application
    Filed: June 2, 2011
    Publication date: June 6, 2013
    Applicant: VIRGINIA TECH INTELLECTUAL PROPERTIES, INC.
    Inventors: Yanyan Ni, Yao-Wei Huang, Xiang-Jin Meng
  • RAGE Fusion Protein Compositions And Methods Of Use
    Publication number: 20130142792
    Abstract: Disclosed are fusion proteins comprising a RAGE polypeptide, wherein the RAGE polypeptide comprises a fragment of a mammalian wild type RAGE peptide and at least one point mutation in the RAGE polypeptide portion of the fusion protein relative to the wild type RAGE peptide. The point mutation may remove and/or alter a glycosylation site or an enzyme cleavage site. Also disclosed are nucleic acids encoding such proteins as well as methods of using such proteins for treating RAGE-mediated pathologies.
    Type: Application
    Filed: October 19, 2010
    Publication date: June 6, 2013
    Inventors: Jeffrey C. Webster, Gregory T. Bleck, Madan Katragadda, Manoj Rajadhyaksha, Bernard N. Violand, Jo-Ann Wentland, Linda Marie Rothlein
  • SEQUENCE-SPECIFIC DNA RECOMBINATION IN EUKARYOTIC CELLS
    Publication number: 20130133092
    Abstract: The present invention relates to a method of sequence specific recombination of DNA in eukaryotic cells utilizing att sequences from the bacteriophage lambda. A particular embodiment of the invention relates to a method further comprising performing the sequence specific recombination of DNA with an Int and a Xis factor. The present invention further relates to vectors containing each of these sequences and their use as medicaments.
    Type: Application
    Filed: November 1, 2012
    Publication date: May 23, 2013
    Inventor: Dr. Peter Droge
  • CELLULAR COMPOSITIONS AND METHODS FOR THEIR PREPARATION AND USE
    Publication number: 20130130374
    Abstract: Methods for preparing a variety of cell (e.g., hepatocyte) preparations and preparations so prepared are described. Uses of such preparations are described. In one embodiment, centrifugal elutriation is used to separate hepatocytes with preferred characteristics. Such hepatocyte preparations may be used for cryopreservation, multiple cryopreservations, in vitro assays, plating and other methods for which preparations of hepatocytes are useful.
    Type: Application
    Filed: August 3, 2011
    Publication date: May 23, 2013
    Applicant: LIFE TECHNOLOGIES CORPORATION
    Inventors: Mark Powers, Rafal Witek, Kirsten Amaral
  • Compositions Comprising High Molecular Weight Hyaluronic Acid and Methods For Producing Same
    Publication number: 20130131009
    Abstract: This invention provides cell culture compositions which produce significant quantities of high molecular weight hyaluronic acid. The cell cultures are obtained from cells of mole rats, such as naked mole rats and blind mole rats. The high molecular weight hyaluronic acid can be collected in the conditioned media of these cell cultures. These cell cultures provide a convenient source of large quantities of high molecular weight hyaluronic acid.
    Type: Application
    Filed: March 24, 2011
    Publication date: May 23, 2013
    Applicant: UNIVERSITY OF ROCHESTER
    Inventors: Vera Gorbunova, Andrei Seluanov, Christopher Hine
  • INFLUENZA VIRUS VACCINE AND USES THEREOF
    Publication number: 20130129761
    Abstract: Provided herein are influenza hemagglutinin stem domain polypeptides, compositions comprising the same, vaccines comprising the same and methods of their use.
    Type: Application
    Filed: March 30, 2011
    Publication date: May 23, 2013
    Applicant: Mount Sinai School of Medicine
    Inventors: Adolfo Garcia-Sastre, Peter Palese, John Steel, Anice C. Lowen
  • Process for the culturing of cells
    Patent number: 8440458
    Abstract: The invention relates to a process for the culturing of cells, preferably E1-immortalized HER cells, more preferably PER.C6 cells in a reactor in suspension in a cell culture medium, wherein the cells produce a biological substance, preferably an antibody, wherein at least one cell culture medium component is fed to the cell culture and wherein the cell culture comprising the cells, the biological substance and cell culture medium is circulated over a separation system and wherein the separation system separates the biological substance from substances having a lower molecular weight than the biological substance and wherein the biological substance is retained in or fed back into the reactor. Preferably part of the substances of lower molecular weight is continuously removed from the cell culture.
    Type: Grant
    Filed: February 15, 2012
    Date of Patent: May 14, 2013
    Assignee: DSM IP Assets B.V.
    Inventors: Gerben Meile Zijlstra, Robert Patrick Hoff, Jacob Schilder